• Presentations will feature next generation Omnipod innovations designed to reduce user effort, new algorithm data, and clinical evidence demonstrating improved time in range
  • Insulet-led sessions will highlight how patient-centered design and strong clinical performance is helping redefine Automated Insulin Delivery (AID) across type 1 and type 2 diabetes

Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 in New Orleans.